The advent of monoclonal antibodies to Tumor necrosis factor-α (TNF), has revolutionized the treatment in rheumatoid arthritis (RA). These agents have proved to be highly efficacious, making remission an achievable goal in RA. Golimumab is a human monoclonal antibody to TNF, which is approved by the US FDA for the treatment of RA, psoriatic arthritis and ankylosing spondylitis since April 2009. Golimumab is a useful addition to the therapeutic armamentarium against rheumatoid arthritis. It has proven efficacy in RA patients with active disease, despite treatment with methotrexate and also found to be useful in patients who have failed on a prior anti-TNF agent. It offers a reasonable alternative to other anti-TNF drugs like infliximab, adalimumab or etanercept. The short-term safety profile, based on short-term RCTs, is reasonable with no differences in total adverse events, serious infections, cancer, tuberculosis or deaths. However, Long-term surveillance studies are needed for safety assessment.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
I have thoroughly enjoyed my participation as a reviewer for Nutrition and Metabolic Insights. I am impressed by the quality of manuscripts submitted for consideration from all over the world. The online review submission process is very well organized and simple to use.
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2014 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)